Noninvasive Cholesterol Testing Becomes Available to Public

(Winnipeg, Canada), a medical diagnostic company focused on developing and commercializing diagnostic tests and risk assessment tools for unmet clinical needs, has signed a Letter of Intent with Gamma-Dynacare Medical Laboratories (Brampton, Canada), one of Canada's largest and medical laboratories, to introduce a laboratory processed format of its PreVu noninvasive cholesterol test technology.

Under the terms of the agreement, Gamma-Dynacare will be responsible for all costs related to the final development stages of the PreVu LP test as well as the development and implementation of an automated system to process the test at a centralized facility. Gamma-Dynacare will also provide logistical support for collection, transportation and results reporting utilizing Gamma's internal infrastructure, which handles tens of thousands of specimens daily, and delivers more than 40 million tests annually. As part of the agreement, Miraculins has awarded Gamma-Dynacare the exclusive rights to process all PreVu LP Tests sold in Canada.

The PreVu LP test noninvasively measures the amount of cholesterol that has been deposited in skin tissues by painlessly and rapidly collecting skin cells from the palm of the hand using a medical adhesive collection device, which would then be sealed and sent to a Gamma-Dynacare laboratory for processing. The sample collection process is easily self-performed, takes 15 sec. to conduct, and does not require fasting.

Related Links:
Miraculins Inc.
Gamma-Dynacare Medical Laboratories